**2015-2016 SEASONAL INFLUENZA VACCINE**

**Recommendations**
The Advisory Committee on Immunization Practices (ACIP) recommendations for the prevention and control of the seasonal influenza (2015-2016 influenza season) are as follows:

“All persons 6 months of age and older are recommended to receive annual influenza vaccination.”

Optimally, vaccination should occur before onset of influenza activity in the community. Health care providers should offer vaccination by October, if possible. Vaccination should continue to be offered as long as influenza viruses are circulating. Children 6 months through 8 years of age who require 2 doses (see algorithm on page 3) should receive the first dose as soon as possible after the vaccine becomes available. To avoid missed opportunities for vaccination, providers should offer vaccination to unvaccinated persons > 6 months during routine health care visits and hospitalizations when vaccine is available.

**2015-2016 Influenza Vaccine Composition**
The U.S. influenza quadrivalent vaccines for 2015-2016 will contain:
- A/California/7/2009 (H1N1)-like virus;
- A/Switzerland/9715293/2013 (H3N2) –like virus;
- B/Phuket/3073/2013-like (Yamagata lineage); and
- B/Brisbane/60/2008-like virus (Victoria lineage).

**Supply**
Production and distribution of seasonal influenza vaccine is never guaranteed. Each spring the IIP requests from the Centers for Disease Control and Prevention (CDC) the number of seasonal flu doses needed based upon provider surveys, population, estimated vaccine uptake, and available funding. The final number of doses made available to the IIP is dependent upon the contracts CDC secures with vaccine manufacturers as well as vaccine production.

This season the FluMist vaccine distribution, from the manufacturer to the CDC, will be later in the season than normal.

The requested 2015-2016 seasonal flu vaccine will be allocated by the CDC to the IIP as it becomes available from the distribution center (McKesson) in waves from August through December. The IIP will distribute the influenza vaccine through provider orders as the vaccine is available. The IIP will only be supplying the quadrivalent formulation of pediatric influenza vaccine.
IMPORTANT NOTICE

FLU EDITION

An Immunization Update from the Idaho Immunization Program (IIP)

**Ordering**
The 2015-2016 seasonal influenza vaccine can be ordered from the IIP through the Immunization Reminder Information System (IRIS) beginning September 8, 2015. The available pediatric influenza vaccine will be listed in IRIS on the Create Order screen.

- Influenza vaccine orders do **not** need to follow your ordering frequency.
- **Influenza vaccine only** orders will require a current refrigerator temperature; however, a full inventory count will not be required. For **influenza vaccine only** orders, click *inventory count*, click *Enter New Count*, and then click *Save & Submit*.
  - Any other vaccines ordered must have a complete physical vaccine count submitted, orders placed without a complete physical vaccine count will be denied.
- Orders may be placed for specific brands and/or presentations; however,
  - If the brand and/or presentation requested was not indicated on the Influenza Survey submitted by your facility and/or is not available, then the order will be denied, and
  - An email will be sent to the primary vaccine coordinator if other brands or presentations are available.
- Orders that are reduced or denied (because the influenza vaccine is not available) will not be tracked and will not be filled at a later date. If an influenza order is denied, then a new order will need to be placed. There will be no backorders.
- Current on-hand counts will be reviewed during the season as vaccine orders are processed (as with all vaccine orders). Stay current with entering doses of influenza vaccine administered into IRIS.

**Multi-dose Vials (MDV) of Influenza Vaccine**
The IIP will be supplying two influenza vaccines in MDV. After the MDV vial has been used for the first time the Fluzone 0.5mL MDV may be used until the expiration date printed on the vial. The **FluLaval 0.5mL MDV may only be administered 28 days after the first use.** Please document the “beyond use date” (28 days from the date the MDV of FluLaval is initially used) on the label along with the initials of the person noting the date.

**Vaccine Information Sheets**
2015-2016 seasonal influenza vaccine information sheets (VIS) are available to order from the IIP. Please go to the IIP’s website at [www.immunizeidaho.com](http://www.immunizeidaho.com) and click on the *Resource Order Form* link on the healthcare provider page or click on the *Related Links* tab in IRIS, then click *Idaho Immunization Program Resource Order Form*.

The 2015-2016 seasonal influenza vaccine information sheets is also available online from the Centers for Disease Control and Prevention - Vaccine Information Statements (VIS) at [http://www.cdc.gov/vaccines/hcp/vis/current-vis.html](http://www.cdc.gov/vaccines/hcp/vis/current-vis.html)
**Dose Recommendations**

Influenza vaccine dosing algorithm for children aged 6 months through 8 years for the 2015-2016 influenza season:

Has the child received ≥2 total doses of trivalent or quadrivalent influenza vaccine before July 1, 2015?*

- Yes
  - 1 dose of 2015-16 influenza vaccine
- No or don’t know
  - 2 doses† of 2015-16 influenza vaccine

*The two doses need not have been received during the same season or consecutive seasons.
†Doses should be administered at least 4 weeks apart.

**Alternate Text:** The algorithm above is a flow chart showing an influenza vaccine dosing for children aged 6 months through 8 years in the United States for the 2015-2016 influenza season. An asterisk footnote symbol appears at the end of the statement, “Has the child received 2 total doses of trivalent or quadrivalent influenza vaccine before July 1, 2015?” The corresponding footnote reads, “The 2 doses need not have been received during the same season or consecutive seasons.” Also, a dagger footnote symbol appears immediately after the phrase “2 doses” in the following statement, “2 doses of 2015-16 influenza vaccine.” The corresponding footnote reads, “Doses should be administered 4 weeks apart.”

**Concurrent Administration of Influenza Vaccine with Other Vaccines**

- Inactivated vaccines do not interfere with the immune response to other inactivated vaccines or to live vaccines.
- Inactivated or live vaccines can be administered simultaneously with LAIV.
- However, after administration of a live vaccine, at least 4 weeks (28-days) should pass before another live vaccine is administered.
  - The 4-day “grace period” may not be applied to the 28-day interval between live vaccines not administered at the same visit.

For additional information please refer to MMWR / August 7, 2015 / 64(30);818-825 or visit [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm?s_cid=mm6430a3_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm?s_cid=mm6430a3_w).
Has the child received ≥2 total doses of trivalent or quadrivalent influenza vaccine before July 1, 2015*?

Yes

1 dose of 2015-16 influenza vaccine

No or don’t know

2 doses† of 2015-16 influenza vaccine

*The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered at least 4 weeks apart.

**Alternate Text**: The algorithm above is a flow chart showing an influenza vaccine dosing for children aged 6 months through 8 years in the United States for the 2015-2016 influenza season. An asterisk footnote symbol appears at the end of the statement, “Has the child received 2 total doses of trivalent or quadrivalent influenza vaccine before July 1, 2015?” The corresponding footnote reads, “The 2 doses need not have been received during the same season or consecutive seasons.” Also, a dagger footnote symbol appears immediately after the phrase “2 doses” in the following statement, “2 doses of 2015-16 influenza vaccine.” The corresponding footnote reads, “Doses should be administered 4 weeks apart.”
PEDIATRIC INFLUENZA VACCINE
Available from the Idaho Immunization Program for the 2015-2016 Season*

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>TRADE NAME</th>
<th>MANUFACTURER</th>
<th>PRESENTATION</th>
<th>MERCURY CONTENT (mcg Hg/0.5mL dose)</th>
<th>AGE GROUP</th>
<th>NUMBER OF DOSES</th>
<th>ROUTE</th>
<th>NDC</th>
<th>CPT CODE</th>
<th>CVX CODES (for electronic exports)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIV4</td>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>0.25mL pre-filled syringe</td>
<td>0</td>
<td>6-35 months</td>
<td>1 or 2</td>
<td>IM**</td>
<td>49281-0515-25</td>
<td>90685</td>
<td>161</td>
</tr>
<tr>
<td>IIV4</td>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>0.5mL pre-filled syringe</td>
<td>0</td>
<td>&gt; 36 months</td>
<td>1 or 2</td>
<td>IM**</td>
<td>49281-0415-50</td>
<td>90686</td>
<td>150</td>
</tr>
<tr>
<td>IIV4</td>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>0.5mL single dose vial</td>
<td>0</td>
<td>&gt; 36 months</td>
<td>1 or 2</td>
<td>IM**</td>
<td>49281-0415-10</td>
<td>90686</td>
<td>150</td>
</tr>
<tr>
<td>IIV4</td>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>5.0mL multi-dose vial</td>
<td>25</td>
<td>&gt; 6 months</td>
<td>1 or 2</td>
<td>IM**</td>
<td>49281-0623-15</td>
<td>90688</td>
<td>158</td>
</tr>
<tr>
<td>IIV4</td>
<td>Fluarix®</td>
<td>GlaxoSmithKline</td>
<td>0.5mL pre-filled syringe</td>
<td>0</td>
<td>≥ 3 years</td>
<td>1 or 2</td>
<td>IM**</td>
<td>58160-0903-52</td>
<td>90686</td>
<td>150</td>
</tr>
<tr>
<td>IIV4</td>
<td>Fluarix®</td>
<td>GlaxoSmithKline</td>
<td>5.0mL multi-dose vial</td>
<td>&lt;25</td>
<td>≥ 3 years</td>
<td>1 or 2</td>
<td>IM**</td>
<td>58160-0898-11</td>
<td>90688</td>
<td>158</td>
</tr>
<tr>
<td>LAIV4</td>
<td>FluMist®</td>
<td>MedImmune</td>
<td>0.2mL sprayer</td>
<td>0</td>
<td>2-49¥ years</td>
<td>1 or 2</td>
<td>IN</td>
<td>66019-0302-10</td>
<td>90672</td>
<td>149</td>
</tr>
</tbody>
</table>

**Abbreviations:** IIV4=Inactivated Influenza Vaccine, Quadrivalent; LAIV4=Live-attenuated Influenza Vaccine; IM=intramuscular injection; IN=intranasal.

* Immunization providers should check Food and Drug Administration--approved prescribing information for 2015--16 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, and precautions. Package inserts for US-licensed vaccines are available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm

** For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration may be found in the ACIP General Recommendations on Immunization (available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm).

¥ FluMist® is shipped refrigerated and stored in the refrigerator at 35°F--46°F (2°C--8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Healthcare providers should consult the medical record, when available, to identify children aged 2–4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2–4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist®.

¥ The IIP supplies FluMist® for patients 2 through 18 years of age.